Comparison of the prognostic value of inflammation-based pathologic and biochemical criteria in patients undergoing potentially curative resection for colorectal cancer

Annals of Surgery

Volumn 249, Issue 5, 2009, Pages 788-793

  Roxburgh, Campbell S D ^a,b   Salmond, Jonathan M ^a   Horgan, Paul G ^a   Oien, Karin A ^a   McMillan, Donald C ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN;

ADULT; AGED; ARTICLE; CANCER CYTODIAGNOSIS; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CELL INFILTRATION; CELLULAR IMMUNITY; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; DUKES STAGE; FEMALE; FOLLOW UP; GLASGOW COMA SCALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOALBUMINEMIA; INFLAMMATION; JASS CRITERIA; KLINTRUP CRITERIA; LAPAROTOMY; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL COUNT; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR; SCORING SYSTEM; SURVIVAL; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

AGED; COLORECTAL NEOPLASMS; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 67649497425     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e3181a3e738     Document Type: Article

References (23)

1. Cancerstats. Available at: www.cancerresearchuk.org. Accessed 2004.
2. McArdle CS, Hole DJ. Outcome following surgery for colorectal cancer: analysis by hospital after adjustment for case-mix and deprivation. Br J Cancer. 2002;86:331-335.
3. Vakilla J, Lotze MT. Inflammation and necrosis promote tumor growth. Nat Cancer Rev. 2004;4:641-648.
4. Mantovani A, Romero P, Palucka AK, et al. Tumor immunity: effector response to tumor and role of the microenvironment. Lancet. 2008;371:771- 783.
5. Jass Jr, Love SB, Northover JM. A new prognostic classification of rectal cancer. Lancet. 1987;1:1303-1306.
6. Ropponen KM, Eskelinen MJ, Lipponen PK, et al. Prognostic value of tumor-infiltrating lymphocytes (TILs) in colorectal cancer. J Pathol. 1997; 182:318-324.
7. Nielsen HJ, Hansen U, Christensen IJ, et al. Independent prognostic value of eosinophil and mast cell infiltration in colorectal cancer tissue. J Pathol. 1999;189:487-495.
8. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313:1960-1964.
9. Klintrup K, Makinen JM, Kauppila S, et al. Inflammation and prognosis in colorectal cancer. Eur J Cancer. 2005;41:2645-2654.
10. McMillan DC, Crozier JE, Canna K, et al. Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer. Int J Colorectal Dis. 2007;22:81- 86.
11. Leitch EF, Chakrabarti M, Crozier JE, et al. Comparison of the prognostic value of selected markers of the systemic inflammatory response in patients with colorectal cancer. Br J Cancer. 2007;97:1266-1270.
12. Ishizuka M, Nagata H, Takagi K, et al. Inflammation-based prognostic score is a novel predictor of postoperative outcome in patients with colorectal cancer. Ann Surg. 2007;246:1047-1051.
13. Dukes CE, Bussey HJ. The spread of rectal cancer and its effect on prognosis. Br J Cancer. 1958;12:309-320.
14. Jass JR, Ajikoka Y, Allen JP, et al. Assessment of invasive growth pattern and lymphocytic infiltration in colorectal cancer. Histopathology. 1996;28:543- 548.
15. Forrest LM, McMillan DC, McArdle CS, et al. Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer. 2003;89:1028- 1030.
16. Crozier JE, Leitch EF, McKee RF, et al. Relationship between emergency presentation, systemic inflammatory response, and cancer specific survival in patients undergoing potentially curative resection for colon cancer. Am J Surg. In press.
17. Du Klos TW, Mold C. C-reactive protein: an activator of innate immunity and a modulator of adaptive immunity. Immunol Res. 2004;30:261-277.
18. Nozoe T, Matsumata T, Sugimachi K. Preoperative elevation of serum C-reactive protein is related to impaired immunity in patients with colorectal cancer. Am J Clin Oncol. 2000;23:263-266.
19. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860- 867.
20. Abramovitch R, Marikovsky M, Meir G, et al. Stimulation of tumor growth by wound-derived growth factors. Br J Cancer. 1999;79:1392-1398.
21. Canna K, Hilmy M, McMillan DC, et al. The relationship between tumor proliferative activity, the systemic inflammatory response, and survival in patients undergoing curative resection for colorectal cancer. Colorectal Dis. 2008;10:663-667.
22. McMillan DC. An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer. Proc Nutr Soc. 2008; 67:257-262.
23. Crozier JE, Mckee RF, Mcardle CS, et al. The presence of a systemic inflammatory response predicts poorer survival in patients receiving adjuvant 5-FU chemotherapy following potentially curative resection for colorectal cancer. Br J Cancer. 2006;94:1833-1836.